Big Pharma Split Corp.
PRM.TO · TSX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | CA$0 | CA$0 | CA$0 | CA$0 |
| % Growth | 493.1% | -92.1% | -26.7% | – |
| Cost of Goods Sold | CA$0 | CA$0 | CA$0 | CA$0 |
| Gross Profit | CA$0 | CA$0 | CA$0 | CA$0 |
| % Margin | 82.9% | 100% | 89.3% | 93.4% |
| R&D Expenses | CA$0 | CA$0 | CA$0 | CA$0 |
| G&A Expenses | CA$0 | CA$0 | CA$0 | CA$0 |
| SG&A Expenses | CA$0 | CA$0 | CA$0 | CA$0 |
| Sales & Mktg Exp. | CA$0 | CA$0 | CA$0 | CA$0 |
| Other Operating Expenses | -CA$0 | CA$0 | CA$0 | -CA$0 |
| Operating Expenses | CA$0 | CA$0 | CA$0 | -CA$0 |
| Operating Income | CA$0 | -CA$0 | CA$0 | CA$0 |
| % Margin | 0.7% | -44.8% | 80.1% | 90.6% |
| Other Income/Exp. Net | -CA$0 | -CA$0 | -CA$0 | -CA$0 |
| Pre-Tax Income | -CA$0 | -CA$0 | CA$0 | CA$0 |
| Tax Expense | CA$0 | -CA$0 | CA$0 | CA$0 |
| Net Income | -CA$0 | -CA$0 | CA$0 | CA$0 |
| % Margin | -29.1% | -44.8% | 80.1% | 90.6% |
| EPS | -0.47 | -0.53 | 1.58 | 3.27 |
| % Growth | 11.3% | -133.5% | -51.7% | – |
| EPS Diluted | -0.47 | -0.53 | 1.58 | 3.27 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | CA$0 | CA$0 | CA$0 | CA$0 |
| Interest Expense | CA$0 | CA$0 | CA$0 | CA$0 |
| Depreciation & Amortization | CA$0 | CA$0 | -CA$0 | -CA$0 |
| EBITDA | CA$0 | -CA$0 | CA$0 | CA$0 |
| % Margin | 1.2% | -44.1% | 80.1% | 90.6% |